Cure Parkinson’s backs multi-drug combinations to tackle the complex roots of Parkinson's

For decades, clinical research into slowing the progression of Parkinson's has relied on a 'silver bullet' strategy, testing standalone monotherapies designed to hit one biological target. However, the early months of 2026 delivered a series of disappointing Phase 2 and Phase 3 clinical trial setbacks, forcing researchers to confront a fundamental flaw. Parkinson’s is not driven by a single failing mechanism. Instead, it is a highly intricate web of cellular dysfunctions running in parallel. In any given individual, the condition might simultaneously involve energy production failures within the mitochondria, chronic neuroinflammation, and severe backlogs in the internal waste disposal system, which is governed by the GBA pathway and lysosomal function. Compounding this complexity, individual genetics dictate which of these cellular failures dominate, meaning a single drug is statistically unlikely to succeed across a broad population. To match this biological reality, a commentary published in the Journal of Parkinson's Disease by co-authors from Cure Parkinson’s and University College London outlines how medical research must transition to rationally designed combination therapies. The authors categorise these multi-drug frameworks into three distinct operational strategies: - Syncretic Combinations: This approach pairs treatments to achieve a synergistic, compounding effect. It functions similarly to the antibiotic combination of amoxicillin and clavulanic acid, where the latter deactivates bacterial defense mechanisms so the primary drug can strike effectively. In neurological research, this could involve pairing an agent that boosts cellular waste clearing with another that shields those same cells from oxidative stress. - Coalistically Additive Combinations: This strategy targets two entirely separate cellular pathways that are individually non-essential but become functional and highly effective only when modulated together. This multi-pronged framework is already widely used to prevent resistance and block multiple escape routes in complex cancers and HIV management. - Targeting Separate Etiological Factors: This model uses a cocktail of treatments to address distinct, parallel causes of cell degradation simultaneously, ensuring that while one drug repairs energy production, another actively reduces toxic protein accumulation. Testing multiple new, unapproved compounds at once presents significant intellectual property and regulatory hurdles. To bypass these roadblocks and accelerate clinical timelines, researchers are heavily focusing on repurposed drugs. Combining existing, safety-proven medications allows scientists to jump straight into early-stage combination testing. To drive this pragmatic shift, Cure Parkinson’s is actively advocating for adaptive, multi-arm clinical trial designs and has committed two million pounds in dedicated funding to move multi-target treatment strategies out of theory and into active human trials.